source
- Alnylam faces slowdown in Amvuttra sales, putting its growth ambitions at riskAlnylam’s market narrative has long hinged on the performance of its cardiomyopathy drug Amvuttra. The company once hoped the therapy could lift its valuation toward the $100 billion range. Recent…
- New governors should prioritize health hires, vaccination data, and a focused agendaMandy Cohen and Ellen Montz, former state health leaders, write an opinion piece aimed at the 21 governors who will assume office on Jan. 1. They draw on their experience at the CDC, state health d…